***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 JUNE 2023**

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Ampicillin | The sponsor requested the delisting of Ampicyn® (ampicillin) from the Pharmaceutical Benefits Scheme (PBS).  The PBAC advised that the delisting of this product may result in an unmet clinical need. The Department sought to retain the product in line with this advice, however the sponsor indicated retention was unviable due to discontinuation of the product and wished to proceed with the delisting. |
| Dipyridamole with aspirin | The sponsor requested the delisting of Diasp SR® (dipyridamole with aspirin) from the PBS.  The PBAC noted the low utilisation, available clinical alternatives and that the sponsor had discontinued supply of the product. The PBAC advised the delisting of this drug would not result in an unmet clinical need. |
| Doxepin | The sponsor requested the delisting of Deptran 10®,Deptran 25® andDeptran 50® (doxepin) from the PBS.  The PBAC noted the range of clinical alternatives available and that the sponsor intended to continue to supply the products privately. The PBAC advised that the delisting of this drug would not result in an unmet clinical need. |
| Pindolol | The sponsor requested the delisting of Barbloc 5® (pindolol) from the PBS.  The PBAC noted the low utilisation, available clinical alternatives and sponsor’s intent to discontinue supply of the product. The PBAC advised the delisting of this drug would not result in an unmet clinical need. |
| Risedronic acid and calcium | The sponsor requested the delisting of Acris Combi® (risedronic acid and calcium) from the PBS.  The PBAC noted the low utilisation, available clinical alternatives and sponsor’s intent to discontinue supply of the product. The PBAC advised the delisting of this product would not result in an unmet clinical need. |

Brendon Wheatley

Director (A/g)

PBAC Assessment Section

Office of Health Technology Assessment

Technology Assessment and Access Division

22 May 2023